Compare TEVA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | ILMN |
|---|---|---|
| Founded | 1901 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5B | 37.0B |
| IPO Year | 1996 | 2000 |
| Metric | TEVA | ILMN |
|---|---|---|
| Price | $40.88 | $271.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $47.17 | ★ $236.55 |
| AVG Volume (30 Days) | ★ 5.3M | 3.7M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.45 | 170.87 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | N/A | $6.48 |
| Revenue Next Year | $3.39 | $6.46 |
| P/E Ratio | ★ N/A | $122.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.83 | $93.50 |
| 52 Week High | $42.02 | $309.35 |
| Indicator | TEVA | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 59.26 |
| Support Level | $30.41 | $116.43 |
| Resistance Level | N/A | $309.35 |
| Average True Range (ATR) | 1.06 | 13.63 |
| MACD | 0.07 | -1.80 |
| Stochastic Oscillator | 69.76 | 32.47 |
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.